© Copyright Nostre Net
Market Research Future (MRFR) has
launched a new study on the global bladder cancer market. The global bladder
cancer market is expected to exhibit a robust 12.5% CAGR over the forecast
period from 2017 to 2023. The report presents a detailed review of the
historical growth trajectory of the global bladder cancer market in order to
provide reliable projections about the probable growth trajectory of the global
bladder cancer market over the forecast period.
Bladder cancer is cancer of the
urinary bladder, which is a temporary reservoir for urine as it passes out of
the body. The kidneys, where urine is produced, are connected to the urinary
bladder, which further releases urine into the ureters and out through the urethra.
Bladder cancer can be brought on by recurrent bladder infections, exposure to
radiation on a consistent basis, and consumption of tobacco in either chewed or
smoked form. The global bladder
cancer market growth is likely to be driven by the growing prevalence of
smoking around the world, as smoking tobacco is seen to be the strongest
causative agent for bladder cancer.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1899
Competitive Analysis:
Leading players in the global
bladder cancer market include AstraZeneca PLC, Celgene Corporation, F.
Hoffman-La Roche AG, Novartis International AG, Sanofi SA, Accord Healthcare,
Bedford Lab, Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline PLC, Eli Lilly
and Company, and Bristol-Myers Squibb Company.
Segmentation:
The global bladder cancer market
is segmented on the basis of type, treatment, diagnosis, end user, and
region.
On the basis of type, the global
bladder cancer market is segmented into transitional cell bladder cancer,
invasive bladder cancer, superficial bladder cancer, squamous cell bladder
cancer, adenocarcinoma, and others.
On the basis of treatment, the
global bladder cancer market is classified into chemotherapy, immunotherapy,
radiation therapy, surgery, and others. Chemotherapy is classified into Valstar
(valrubicin), Javlor (vinflunine ditartrate), Mitomycin C, Gemcitabine and
cisplatin chemotherapy (GemCis), and others.
On the basis of diagnosis, the
global bladder cancer market is classified into urine lab tests, cystoscopy,
biopsy, imaging tests, and others. The urine lab tests segment is further
classified into urinalysis, urine cytology, urine culture, and urine tumor
marker test. The imaging test segment is further divided into intravenous
pyelogram (IVP), computed tomography (CT), magnetic resonance imaging (MRI),
and bladder ultrasound.
On the basis of end user, the
global bladder cancer market is classified into hospitals, clinics, cancer care
centers, and others.
Regional Analysis:
The global bladder cancer market
is segmented into the Americas, Europe, Asia Pacific, and the Middle East and
Africa on the basis of geography.
The Americas is the leading
geographical segment of the global bladder cancer market and is likely to hold
on to the top position over the forecast period due to the increasing
prevalence of bladder cancer and the rapid development of innovative, advanced
cancer therapies. The developed healthcare sector in this region has led to the
development of targeted therapies and other innovations, which is likely to be
a major driver for the bladder cancer market in North America over the forecast
period. Considerable research efforts have also been directed at enabling early
diagnosis of bladder cancer, so that the treatment can have more efficacy.
Europe is also a major regional
player in the global bladder cancer market and is likely to remain a leading
contributor to the global bladder cancer market over the forecast period due to
the presence of a highly advanced healthcare sector, especially in Western
Europe. Asia Pacific is likely to exhibit strong growth in the bladder cancer
market over the forecast period.
Browse Full Report @ https://www.marketresearchfuture.com/reports/bladder-cancer-market-1899
The Wall